NasoDeliv
Internasal Vaccine Delivery
Enhanced Immune Modulation
Poor vaccine efficacy is attributed to a suboptimal immune response and can be linked to administration route. Systemic vaccines are generally limited to systemic immunity and fail to induce the mucosal immune system, the body’s first line of defence against outside pathogens at surfaces like the nose, lungs, mouth, eyes, and GI tract. Mucosal vaccines have the potential to create stronger immune defences at the initial site of pathogen entry.
Current Challenges
A major commercialisation challenge with mucosal vaccines has been the inefficient antigen uptake, its rapid mucociliary clearance, size-restricted permeation across epithelial barriers and absence of safe human mucosal adjuvants.
NasoDeliv Features
BioCyto is developing an intranasal vaccine nanoparticle platform that activates strong immune responses and to overcome volatile mucosal environment limitations. Studies have shown that nanoparticles protect therapeutic cargo from proteolytic degradation and improve uptake into immune cells. Additionally, nanoparticles can exert adjuvant properties and controlled cargo release to prolong immune responses.
NasoDeliv is being developed to cross the air-blood tissue barrier to enter the body’s circulatory system and are taken up by antigen-presenting cells and delivered to lymph nodes, thymus and spleen.